Cheyne Capital Management UK LLP acquired a new position in shares of Kite Pharma Inc (NASDAQ:KITE) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 990,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,668,000. Kite Pharma comprises approximately 6.0% of Cheyne Capital Management UK LLP’s holdings, making the stock its 9th largest position. Cheyne Capital Management UK LLP owned approximately 1.73% of Kite Pharma as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. purchased a new stake in shares of Kite Pharma in the second quarter valued at about $124,000. Comerica Bank purchased a new stake in shares of Kite Pharma in the second quarter valued at about $201,000. Biondo Investment Advisors LLC purchased a new stake in shares of Kite Pharma in the second quarter valued at about $218,000. Capital Investment Advisory Services LLC purchased a new stake in shares of Kite Pharma in the second quarter valued at about $238,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in shares of Kite Pharma in the second quarter valued at about $238,000. Hedge funds and other institutional investors own 87.72% of the company’s stock.

Shares of Kite Pharma Inc (KITE) traded up $0.20 during trading hours on Thursday, reaching $179.99. 100 shares of the company’s stock were exchanged, compared to its average volume of 1,652,408. Kite Pharma Inc has a 12-month low of $39.82 and a 12-month high of $179.99.

In other news, SVP Jeffrey Wiezorek sold 5,283 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $179.66, for a total value of $949,143.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Cynthia M. Butitta sold 4,228 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $179.66, for a total transaction of $759,602.48. Following the completion of the transaction, the chief operating officer now owns 125,795 shares of the company’s stock, valued at $22,600,329.70. The disclosure for this sale can be found here. Insiders have sold 48,936 shares of company stock valued at $8,791,842 in the last quarter. Company insiders own 14.00% of the company’s stock.

Several brokerages have recently commented on KITE. SunTrust Banks, Inc. downgraded shares of Kite Pharma from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Wedbush upgraded shares of Kite Pharma from an “underperform” rating to a “neutral” rating in a report on Tuesday, August 29th. BTIG Research downgraded shares of Kite Pharma from a “buy” rating to a “neutral” rating in a report on Monday, August 28th. Jefferies Group LLC reiterated a “buy” rating and issued a $135.00 target price (up previously from $121.00) on shares of Kite Pharma in a report on Wednesday, August 9th. Finally, Canaccord Genuity set a $120.00 target price on shares of Kite Pharma and gave the company a “buy” rating in a report on Wednesday, August 9th. Thirteen investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $94.68.

WARNING: This piece of content was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/16/cheyne-capital-management-uk-llp-takes-position-in-kite-pharma-inc-kite.html.

Kite Pharma Profile

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Stock Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related stocks with our FREE daily email newsletter.